The recombinant Llama VHH-Human IgG Antibody from SignalChem Biotech is a high-sensitivity SARS-CoV-2 spike protein detection assay. The particular activity was quantified using a couple of Functional ELISA systems, and this was done by testing the binding ability of the nanobody to SARS-CoV-2 spike protein.
SARS-CoV-2—the severe acute respiratory syndrome-related novel coronavirus—has been responsible for causing the pandemic of respiratory diseases (COVID-19) throughout the world in 2020.1
The spike glycoprotein (S) of coronavirus is part of the type I transmembrane protein that contains two subunits, S1 and S2.2 These subunits are also known to be the main components to attach to host cells via the interaction with angiotensin-converting enzyme 2 (ACE2).3
A receptor binding domain (RBD) of S1 is capable of identifying the cell surface receptor, while the RBD mutation could result in higher motility rate.3
The binding ability measured in a functional ELISA. Immobilized Anti 2019-nCoV Spike Protein Llama heavy-chain (C19S1-641HL) binds 2019-nCoV Spike protein RBD (C19SD-241H) that can be detected at picomol level using Anti 2019-nCoV Spike Protein hIgG Antibody (C19S1-61H). Image Credit: SignalChem Biotech Inc.
The binding of Anti 2019-nCoV Spike Protein Llama heavy-chain (C19S1-641HL) to 2019-nCoV RBD (C19SD-G241H) determined by ELISA. Image Credit: SignalChem Biotech Inc.
- Zhou P, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270–89.
- Xiao X, et al: The SARS-CoV S glycoprotein. Cell Mol Life Sci. 2004, 61 (19-20): 2428–30.
- Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235.